OPT
Price
$3.41
Change
+$0.23 (+7.23%)
Updated
Mar 17 closing price
Capitalization
524.82M
12 days until earnings call
QLGN
Price
$1.90
Change
+$0.14 (+7.95%)
Updated
Aug 15 closing price
Capitalization
3.11M
Interact to see
Advertisement

OPT vs QLGN

Header iconOPT vs QLGN Comparison
Open Charts OPT vs QLGNBanner chart's image
Opthea
Price$3.41
Change+$0.23 (+7.23%)
Volume$3.03K
Capitalization524.82M
Qualigen Therapeutics
Price$1.90
Change+$0.14 (+7.95%)
Volume$99.35K
Capitalization3.11M
OPT vs QLGN Comparison Chart in %
Loading...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OPT vs. QLGN commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OPT is a Hold and QLGN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (OPT: $3.41 vs. QLGN: $1.90)
Brand notoriety: OPT and QLGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OPT: 100% vs. QLGN: 9%
Market capitalization -- OPT: $524.82M vs. QLGN: $3.11M
OPT [@Biotechnology] is valued at $524.82M. QLGN’s [@Biotechnology] market capitalization is $3.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OPT’s FA Score shows that 0 FA rating(s) are green whileQLGN’s FA Score has 1 green FA rating(s).

  • OPT’s FA Score: 0 green, 5 red.
  • QLGN’s FA Score: 1 green, 4 red.
According to our system of comparison, QLGN is a better buy in the long-term than OPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QLGN’s TA Score shows that 3 TA indicator(s) are bullish.

  • QLGN’s TA Score: 3 bullish, 6 bearish.

Price Growth

OPT (@Biotechnology) experienced а 0.00% price change this week, while QLGN (@Biotechnology) price change was +4.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

OPT is expected to report earnings on Aug 28, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OPT($525M) has a higher market cap than QLGN($3.11M). OPT YTD gains are higher at: -13.176 vs. QLGN (-54.869). QLGN has higher annual earnings (EBITDA): -6.73M vs. OPT (-218.88M). OPT has more cash in the bank: 132M vs. QLGN (388K). QLGN has less debt than OPT: QLGN (1.43M) vs OPT (157M). OPT has higher revenues than QLGN: OPT (87.7K) vs QLGN (0).
OPTQLGNOPT / QLGN
Capitalization525M3.11M16,897%
EBITDA-218.88M-6.73M3,252%
Gain YTD-13.176-54.86924%
P/E RatioN/A0.00-
Revenue87.7K0-
Total Cash132M388K34,021%
Total Debt157M1.43M10,948%
FUNDAMENTALS RATINGS
OPT vs QLGN: Fundamental Ratings
OPT
QLGN
OUTLOOK RATING
1..100
4951
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5897
P/E GROWTH RATING
1..100
10047
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QLGN's Valuation (23) in the null industry is significantly better than the same rating for OPT (94). This means that QLGN’s stock grew significantly faster than OPT’s over the last 12 months.

QLGN's Profit vs Risk Rating (100) in the null industry is in the same range as OPT (100). This means that QLGN’s stock grew similarly to OPT’s over the last 12 months.

QLGN's SMR Rating (100) in the null industry is in the same range as OPT (100). This means that QLGN’s stock grew similarly to OPT’s over the last 12 months.

OPT's Price Growth Rating (58) in the null industry is somewhat better than the same rating for QLGN (97). This means that OPT’s stock grew somewhat faster than QLGN’s over the last 12 months.

QLGN's P/E Growth Rating (47) in the null industry is somewhat better than the same rating for OPT (100). This means that QLGN’s stock grew somewhat faster than OPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OPTQLGN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IZEA4.200.25
+6.33%
IZEA Worldwide
ATEX22.340.65
+3.00%
Anterix
SCI80.66-0.01
-0.01%
Service Corp
IVP1.04-0.10
-8.77%
Inspire Veterinary Partners Inc
NEGG101.02-27.07
-21.13%
Newegg Commerce Inc

QLGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, QLGN has been loosely correlated with NTLA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if QLGN jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QLGN
1D Price
Change %
QLGN100%
+7.95%
NTLA - QLGN
35%
Loosely correlated
+0.83%
PHIO - QLGN
32%
Poorly correlated
-0.46%
ZLDAF - QLGN
29%
Poorly correlated
N/A
MNOV - QLGN
28%
Poorly correlated
+0.77%
JAGX - QLGN
28%
Poorly correlated
+1.45%
More